LTC-004

N/A

Report date: 2024/07/12 15:59:15

Base Information

Drug NameLTC-004
Drug Alias NameLTC004LTC-004
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor subunit gamma agonistsInterleukin-2 receptor beta chain agonists
TargetsInterleukin-2 receptor subunit gammaInterleukin-2 receptor beta chain
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLeto Laboratories Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLeto Laboratories Co LtdLetoLab LtdTianjin Medical University Cancer Institute And Hospital +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A